<DOC>
	<DOCNO>NCT02448797</DOCNO>
	<brief_summary>Adjuvant therapy prove effective treat early stage less advanced non-small-cell lung cancer . This study design evaluate efficacy icotinib adjuvant therapy treat stage II-IIIA non-small cell lung cancer patient EGFR mutation . The primary endpoint disease-free survival .</brief_summary>
	<brief_title>Icotinib Versus Vinorelbine/Platinum Adjuvant Therapy Stage II-IIIA Non-small Cell Lung Cancer With EGFR-mutation</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Pathologically confirm lung adenocarcinoma surgical resection Stage IIIIIA disease accord 7th edition TNM stag Positive EGFR gene mutation ( 19/21 ) ECOG 01 At least 1year life expectancy Adequate organ function Previous systemic antitumor therapy , include chemotherapy target therapy ( Including limit monoclonal antibody , small molecule tyrosine kinase inhibitor , etc Other coexist malignancy malignancy diagnose within last 5 year exception basal cell carcinoma cervical cancer situ Pneumonectomy right lung Any unresolved chronic toxicity previous anticancer therapy Allergic study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>